Physician

Khalid M Bhatti, M.D.

According to 2025 Medicare claims, Khalid Bhatti, M.D. (NPI: 1497824114) practices nephrology in the Elizabethtown, KY market, with the plurality of this provider's patient population coming from Hardin, KY. This provider's primary affiliated billing organization is NEPHROLOGY ASSOCIATES OF CENTRAL KENTUCKY LLC (NPI: 1528062460; TIN: 611379420) and primary practice location at 42701-2503.

Bhatti's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 742 traditional Medicare patients, billed 2,854 HCPCS/CPT codes, and received $228,604 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 4,418 prescription claims across 540 beneficiaries totaling $579,115 in drug costs, led by Xphozah (Tenapanor Hcl). DME data shows 108 claims. Open Payments data shows 59 records totaling $1,113. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $519,636 to $228,604. Similarly, Part D prescription costs have declined steadily, from $900,227 to $579,115. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $8,587 to $1,659.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,203	6,154	$519,636
2016	1,282	7,277	$657,130
2017	1,456	8,477	$777,361
2018	1,726	9,402	$911,221
2019	1,470	8,126	$788,698
2020	1,207	5,610	$506,900
2021	961	4,157	$375,392
2022	944	4,011	$347,622
2023	765	2,814	$256,955
2024	742	2,854	$228,604

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	520	5,397	$900,227
2016	557	5,550	$868,614
2017	616	6,228	$1,035,351
2018	622	5,345	$553,981
2019	593	5,054	$562,896
2020	567	5,036	$628,790
2021	571	4,985	$724,156
2022	541	4,307	$512,135
2023	529	4,188	$561,040
2024	540	4,418	$579,115

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	60	317	$9,384
2016	12	323	$19,460
2017	30	413	$23,183
2018	20	343	$19,092
2019	16	278	$9,877
2020	17	270	$8,707
2021	N/R	183	$6,878
2022	N/R	101	$19,208
2023	N/R	106	$8,485
2024	N/R	108	$1,573

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	141	162	$121
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	227	677	$84
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	247	420	$81
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	187	277	$55
99442	Telephone medical discussion with physician, 11-20 minutes	97	121	$43

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xphozah	Tenapanor Hcl	34	1,200	$116,088
Farxiga	Dapagliflozin Propanediol	107	4,530	$84,536
Eliquis	Apixaban	40	1,614	$30,978
Jardiance	Empagliflozin	49	1,650	$30,477
Lokelma	Sodium Zirconium Cyclosilicate	33	1,350	$27,202

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	33	$565
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	36	$414
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	12	$364
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	15	$222
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	12	$8

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	59	$1,113	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Khalid M. Bhatti, M.D.?

Tedicare shows public-source Medicare data for Khalid M. Bhatti, M.D. (NPI 1497824114), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Khalid M. Bhatti, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Khalid M. Bhatti, M.D.?

Khalid M. Bhatti, M.D. is linked to NEPHROLOGY ASSOCIATES OF CENTRAL KENTUCKY LLC (billing NPI 1528062460) in the available physician profile data.

Does Khalid M. Bhatti, M.D. have Open Payments data?

Khalid M. Bhatti, M.D. has 59 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.